Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.
A dosagem é determinada pela indicação, gravidade e local da infecção, suscetibilidade à ciprofloxacina do (s) organismo (s) causador (es), função renal do paciente e, em crianças e adolescentes, o peso corporal.
A duração do tratamento depende da gravidade da doença e do curso clínico e bacteriológico.
O tratamento de infecções devido a certas bactérias (por exemplo, Pseudomonas aeruginosa , Acinetobacter ou Staphylococci) pode exigir doses mais altas de ciprofloxacina e co-administração com outros agentes antibacterianos adequados.
O tratamento de algumas infecções (por exemplo, doença inflamatória pélvica, infecções intra-abdominais, infecções em pacientes neutropênicos e infecções de ossos e articulações) pode exigir a administração concomitante com outros agentes antibacterianos apropriados, dependendo dos patógenos envolvidos.
Adultos
Indications |
Daily dose in mg |
Total duration of treatment (potentially including initial parenteral treatment with ciprofloxacin) |
|
Infections of the lower respiratory tract |
500 mg twice daily to 750 mg twice daily |
7 to 14 days |
|
Infections of the upper respiratory tract |
Acute exacerbation of chronic sinusitis |
500 mg twice daily to 750 mg twice daily |
7 to 14 days |
Chronic suppurative otitis media |
500 mg twice daily to 750 mg twice daily |
7 to 14 days |
|
Malignant external otitis |
750 mg twice daily |
28 days up to 3 months |
|
Urinary tract infections (see section 4.4) |
Uncomplicated cystitis |
250 mg twice daily to 500 mg twice daily |
3 days |
In pre-menopausal women, 500 mg single dose may be used |
|||
Complicated cystitis, Uncomplicated pyelonephritis |
500 mg twice daily |
7 days |
|
Complicated pyelonephritis |
500 mg twice daily to 750 mg twice daily |
at least 10 days, it can be continued for longer than 21 days in some specific circumstances (such as abscesses) |
|
Prostatitis |
500 mg twice daily to 750 mg twice daily |
2 to 4 weeks (acute) to 4 to 6 weeks (chronic) |
|
Genital tract infections |
Gonococcal uretritis and cervicitis |
500 mg as a single dose |
1 day (single dose) |
Epididymo-orchitis and pelvic inflammatory diseases |
500 mg twice daily to 750 mg twice daily |
at least 14 days |
|
Infections of the gastro-intestinal tract and intra-abdominal infections |
Diarrhoea caused by bacterial pathogens including Shigella spp. other than Shigella dysenteriaetype 1 and empirical treatment of severe travellers' diarrhoea |
500 mg twice daily |
1 day |
Diarrhoea caused by Shigella dysenteriae type 1 |
500 mg twice daily |
5 days |
|
Diarrhoea caused by Vibrio cholerae |
500 mg twice daily |
3 days |
|
Typhoid fever |
500 mg twice daily |
7 days |
|
Intra-abdominal infections due to Gram-negative bacteria |
500 mg twice daily to 750 mg twice daily |
5 to 14 days |
|
Infections of the skin and soft tissue |
500 mg twice daily to 750 mg twice daily |
7 to 14 days |
|
Bone and joint infections |
500 mg twice daily to 750 mg twice daily |
max. of 3 months |
|
Neutropenic patients with fever that is suspected to be due to a bacterial infection Ciprofloxacin should be co-administered with appropriate antibacterial agent(s) in accordance to official guidance. |
500 mg twice daily to 750 mg twice daily |
Therapy should be continued over the entire period of neutropenia |
|
Prophylaxis of invasive infections due to Neisseria meningitidis |
500 mg as a single dose |
1 day (single dose) |
|
Inhalation anthrax post-exposure prophylaxis and curative treatment for persons able to receive treatment by oral route when clinically appropriate. Drug administration should begin as soon as possible after suspected or confirmed exposure. |
500 mg twice daily |
60 days from the confirmation of Bacillus anthracis exposure |
População pediátrica
Indications |
Daily dose in mg |
Total duration of treatment (potentially including initial parenteral treatment with ciprofloxacin) |
Cystic fibrosis |
20 mg/kg body weight twice daily with a maximum of 750 mg per dose. |
10 to 14 days |
Complicated urinary tract infections and pyelonephritis |
10 mg/kg body weight twice daily to 20 mg/kg body weight twice daily with a maximum of 750 mg per dose. |
10 to 21 days |
Inhalation anthrax post-exposure prophylaxis and curative treatment for persons able to receive treatment by oral route when clinically appropriate. Drug administration should begin as soon as possible after suspected or confirmed exposure. |
10 mg/kg body weight twice daily to 15 mg/kg body weight twice daily with a maximum of 500 mg per dose. |
60 days from the confirmation of Bacillus anthracis exposure |
Other severe infections |
20 mg/kg body weight twice daily with a maximum of 750 mg per dose. |
According to the type of infections |
Pacientes idosos
Os pacientes idosos devem receber uma dose selecionada de acordo com a gravidade da infecção e a depuração da creatinina do paciente.
Pacientes com insuficiência renal e hepática
Doses recomendadas de início e manutenção para pacientes com insuficiência renal:
Creatinine Clearance [mL/min/1.73 m2] |
Serum Creatinine [µmol/L] |
Oral Dose [mg] |
> 60 |
< 124 |
See Usual Dosage. |
30-60 |
124 to 168 |
250-500 mg every 12 h |
<30 |
>169 |
250-500 mg every 24 h |
Patients on haemodialysis |
>169 |
250-500 mg every 24 h (after dialysis) |
Patients on peritoneal dialysis |
>169 |
250-500 mg every 24 h |
Em pacientes com insuficiência hepática, não é necessário ajuste da dose.
A dose em crianças com insuficiência renal e / ou hepática não foi estudada.
Modo de administração
Os comprimidos devem ser engolidos sem mastigar com líquido. Eles podem ser tomados independentemente das refeições. Se tomado com o estômago vazio, a substância ativa é absorvida mais rapidamente. Os comprimidos de ciprofloxacina não devem ser tomados com produtos lácteos (por exemplo, leite, iogurte) ou suco de frutas enriquecido com minerais (por exemplo, suco de laranja com cálcio) (ver seção 4.5).
Em casos graves ou se o paciente não puder tomar comprimidos (por exemplo, pacientes com nutrição enteral), recomenda-se iniciar a terapia com ciprofloxacina intravenosa até que seja possível uma mudança para administração oral.
Grupo de Produto : Drogas Terminadas > Antibiótico e antivírus
Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.
Fill in more information so that we can get in touch with you faster
Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.